CRINETICS PHARMACEUTICALS IN (CRNX) Stock Balance Sheet
NASDAQ:CRNX • US22663K1079
Current stock price
35.57 USD
-0.25 (-0.7%)
At close:
35.57 USD
0 (0%)
After Hours:
| 2025 (2025-12-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 101.54M | 264.55M | 54.90M | 32.70M | 200.70M | |||
| Marketable Securities | 926.35M | 1.09B | 503.66M | 301.80M | 133.00M | |||
| Receivables | 592.00K | 8.39M | 9.10M | 2.30M | 1.50M | |||
| Inventories | 2.02M | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 17.84M | 12.93M | 6.50M | 8.50M | 9.50M | |||
| Total Current Assets | 1.05B | 1.38B | 574.15M | 345.20M | 344.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 54.79M | 55.58M | 57.43M | 5.00M | 4.70M | |||
| Investments And Advances | N/A | 0.00 | 470.00K | 0.00 | 1.00M | |||
| Other Non-Current Assets | 23.13M | 3.63M | 3.30M | 2.00M | 600.00K | |||
| Total Non-Current Assets | 77.91M | 59.20M | 61.20M | 7.00M | 6.30M | |||
| TOTAL ASSETS | 1.13B | 1.43B | 635.35M | 352.20M | 351.00M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 61.23M | 51.66M | 35.34M | 18.60M | 7.50M | |||
| Accounts Payable | 22.61M | 5.85M | 6.55M | 6.90M | 8.50M | |||
| Other Current Liabilities | 1.24M | 2.18M | 2.06M | 2.20M | N/A | |||
| Total Current Liabilities | 85.07M | 59.68M | 43.94M | 27.70M | 16.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 49.10M | 50.10M | 52.30M | 8.10M | 3.10M | |||
| Total Non-Current Liabilities | 49.10M | 50.10M | 52.30M | 8.10M | 3.10M | |||
| TOTAL LIABILITIES | 134.17M | 109.79M | 96.25M | 35.80M | 19.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.42B | -952.11M | -653.70M | -439.20M | -275.30M | |||
| Additional Paid In Capital | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 2.41B | 2.28B | 1.19B | 759.40M | 607.60M | |||
| Treasury Stock | -112.00K | N/A | N/A | N/A | N/A | |||
| Other Shareholders' Equity | 1.86M | 963.00K | 977.00K | -3.90M | -400.00K | |||
| Shares Outstanding | 95.58M | 92.93M | 68.17M | 53.90M | 47.60M | |||
| Tangible Book Value per Share | 10.38 | 14.26 | 7.91 | 5.87 | 6.97 | |||
| Total Shareholders' Equity | 992.08M | 1.32B | 539.11M | 316.30M | 331.90M | |||
| TOTAL LIABILITIES AND EQUITY | 1.13B | 1.43B | 635.35M | 352.20M | 351.00M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 12.32 | 23.04 | 13.07 | 12.46 | 21.54 | |||
| Return On Assets (ROA) | -41.32% | -20.80% | -33.77% | -46.54% | -30.67% | |||
| Return On Equity (ROE) | -46.90% | -22.52% | -39.79% | -51.82% | -32.43% | |||
All data in USD , ROIC based on taxRate of 0.21